Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Gadodiamide
Drug ID BADD_D00985
Description Gadodiamide is a paramagnetic gadolinium-based contrast agent (GBCA) that is used in MR imaging procedures to assist in the visualization of blood vessels. It is intravenously injected and is commonly marketed under the trade name Omniscan.
Indications and Usage For intravenous use in MRI to visualize lesions with abnormal vascularity (or those thought to cause abnormalities in the blood-brain barrier) in the brain (intracranial lesions), spine, and associated tissues.
Marketing Status approved; investigational
ATC Code V08CA03
DrugBank ID DB00225
KEGG ID D04284
MeSH ID C064925
PubChem ID 60754
TTD Drug ID D03EEH
NDC Product Code 0407-0691; 0407-0690; 71806-069
UNII 84F6U3J2R6
Synonyms gadodiamide | Gd-DTPA bis-(methylamide) | Gd-DTPA-BMA | Omniscan | Omniscan Unique Softpack
Chemical Information
Molecular Formula C16H28GdN5O9
CAS Registry Number 122795-43-1
SMILES CNC(=O)CN(CCN(CCN(CC(=O)NC)CC(=O)[O-])CC(=O)[O-])CC(=O)[O-].O.[Gd+3]
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Throat irritation22.12.03.029; 07.05.05.0370.108123%Not Available
Throat tightness19.01.02.005; 22.12.03.0310.038412%Not Available
Tinnitus17.04.07.004; 04.04.01.0020.010670%
Tremor17.01.06.0020.024897%
Urinary incontinence20.02.02.010; 17.05.01.0080.007113%
Urticaria23.04.02.001; 10.01.06.0010.210556%
Vision blurred17.17.01.010; 06.02.06.0070.034856%
Visual impairment06.02.10.0130.029876%Not Available
Vomiting07.01.07.0030.173567%
Mobility decreased15.03.05.023; 17.02.05.018; 08.01.03.0300.010670%Not Available
Joint range of motion decreased15.01.02.0060.007113%
Brain oedema17.07.02.003; 12.01.10.0100.007113%
Skin fibrosis23.03.03.0610.014227%Not Available
Skin tightness23.03.03.0180.017783%Not Available
Deep vein thrombosis24.01.02.003--Not Available
Skin induration23.03.03.0200.021340%
Eye pruritus06.04.05.0060.015649%Not Available
Musculoskeletal stiffness15.03.05.0270.014227%Not Available
Skin burning sensation23.03.03.021; 17.02.06.0090.014227%Not Available
Paraesthesia oral07.05.05.035; 17.02.06.0080.007113%Not Available
Cognitive disorder19.21.02.001; 17.03.03.0030.014227%
Vasodilation procedure25.03.01.001--Not Available
Induration08.01.03.0200.007113%Not Available
Hot flush08.01.03.027; 24.03.01.005; 21.02.02.0010.007113%
Inflammation10.02.01.089; 08.01.05.0070.010670%Not Available
Mental disorder19.07.01.0020.007113%Not Available
Feeling of body temperature change08.01.09.0120.007113%Not Available
Sensation of foreign body08.01.09.0020.007113%Not Available
Adverse drug reaction08.06.01.009--Not Available
Muscle contracture15.03.05.0240.007113%Not Available
The 5th Page    First    Pre   5 6    Next   Last    Total 6 Pages